采用原位免疫荧光杂交法(fluorescence in situ hybridization, FISH)检测ALK融合基因阳性,一线化疗失败后给予crizotinib治疗,250 mg,2次/d。按照实体瘤疗效评价标准1.1版(Response Evaluation Criteriation in Solid Tumours, RECIST v1.1)评价客观疗效,采用骨髓活检评价骨髓转移瘤疗效。按照不良反应通用术语标准4.0版(Common Terminology Criteria for Adverse Events v4.0, CTC AE v4.0)评估用药期间发生的不良事件。. Here, ALK is linked to neoplasm.